RNA polymerase

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Retrieved on: 
Wednesday, December 7, 2022
SYK, Squamous cell carcinoma, Cohort study, CDK9, Enzyme, Bio, Chordoma, Sarcoma, SAN, Security (finance), Ovarian cancer, RNA polymerase II, RNA polymerase, Cancer, Cmax, Large-cell lung carcinoma, MYC, KRON, Research, Plasma, PK, Kronos, Drug, COVID-19, CDK, Patient, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from the ongoing dose-escalation stage of its Phase 1/2 clinical trial of KB-0742, the company’s cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified and transcriptionally addicted solid tumors, support a recommended Phase 2 dose (RP2D) of 60 mg.

Key Points: 
  • This level of target engagement is consistent with demonstrating anti-tumor activity based on preclinical models.
  • A total of 26 patients have been enrolled and treated in the dose escalation phase of the study.
  • The long plasma half-life enables KB-0742 to achieve sustained pharmacologically active concentrations while avoiding potentially toxic peak (Cmax) concentrations.
  • Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.

FDA Clears Thermo Scientific EliA RNA Pol III and EliA Rib-P Tests for Use in U.S.

Retrieved on: 
Thursday, June 9, 2022
FDA, Medical Devices, Other Health, Health, Genetics, Science, Applied Biosystems, Meta-analysis, Lupus, Arthritis, Research, Patheon, Autoantibody, Mayo Clinic College of Medicine and Science, SLE, Systemic scleroderma, Invitrogen, American College, Autoimmunity Reviews, Immunoglobulin G, PPD, Connective tissue, Scleroderma, FDA, Patient, Medical laboratory, RNA polymerase III, Fisher Scientific, BMC Medicine, Laboratory, Health, Review, Antibody, Diagnosis, Thermo Fisher Scientific, Autoimmunity, CTD, Efficiency, Systemic, Pharmaceutical Services Negotiating Committee, Elia, RNA polymerase, Mindful Scientific Inc., Medical device, Vaccine, Dermatology

Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
  • [2] The EliA RNA Pol III test completes a criteria based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
    A subset of SLE patients present with monospecific Ribosomal P antibodies.
  • The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases.
  • For more information on the Thermo Scientific EliA RNA Pol III and EliA Rib-P tests, please visit https://www.thermofisher.com/phadia .

RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor Drug Pipeline Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 3, 2022
Pharmaceutical, Health, Clinical Trials, RNA-dependent RNA polymerase, Therapy, RNA polymerase, RNA, Vaccine

The "RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor development.
  • The report assesses the active RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
  • Offers detailed therapeutic product profiles of RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

Retrieved on: 
Monday, November 29, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), Safety, Cell, PD, PK, MYC, Forward-looking statement, Plasma, AML, Cancer, SEC, SAN, RNA polymerase, U.S. Securities and Exchange Commission, RNA polymerase II, Nature, COVID-19, KRON, SYK, Nasdaq, Research, GLOBE, CDK9, LinkedIn, Factor X, Kronos, Phosphorylation, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the company’s internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors.

Key Points: 
  • An interim analysis of the ongoing dose escalation stage of the trial (data cut-off October 29) demonstrated a differentiated pharmacokinetic (PK) profile and evidence of target engagement for KB-0742.
  • This long plasma half-life supports Kronos Bios approach to defining a therapeutic window for CDK9 inhibition.
  • These early data are encouraging, and we look forward to continuing the trial and establishing a recommended Phase 2 dose.
  • The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

The Science Behind the Shot: Biotech Tools Developed at Brookhaven Lab Fundamental to Making COVID-19 Vaccines

Retrieved on: 
Tuesday, May 25, 2021
Nucleic acids, Branches of biology, RNA, Enzymes, Biology, Molecular biology, Biotechnology, RNA polymerase, Virus, T7, Polymerase

T7 is a virus that infects E. coli bacteria and commandeers those cells to make copies of the virus.

Key Points: 
  • T7 is a virus that infects E. coli bacteria and commandeers those cells to make copies of the virus.
  • Shortly thereafter, Studier and his team found a way to direct T7s prolific copying capability toward making things other than more T7s.
  • I had wondered casually if T7 RNA polymerase might be involved in making the RNA vaccines, mused Studier, now a senior biophysicist Emeritus.
  • Brookhaven National Laboratory is supported by the U.S. Department of Energys Office of Science.

DGAP-News: Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2020

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Gene expression, Nucleic acids, Biology, Amatoxin, RNA polymerase II, Messenger RNA, RNA polymerase, Transcription, Polymerase, Amanitin, alpha-Amanitin, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.

Key Points: 
  • Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.
  • They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells.
  • This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DNA-Dependent RNA Polymerase Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 22, 2019
Health, Pharmaceutical, Branches of biology, Biology, Gene expression, Molecular biology, RNA, Biotechnology, Nucleic acids, RNA polymerase, DNA, Reverse transcriptase, Transcription

The "DNA-Dependent RNA Polymerase Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "DNA-Dependent RNA Polymerase Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • DNA-Dependent RNA Polymerase Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across DNA-Dependent RNA Polymerase Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of DNA-Dependent RNA Polymerase Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine